Vol 5, No 1 (2004): Practical Diabetology
Research paper
Published online: 2004-02-02
Cost of Diabetes Type 2 in Poland (CODIP)
Diabetologia Praktyczna 2004;5(1):1-8.
Abstract
INTRODUCTION. The Cost of Diabetes Type 2 in Poland (CODIP) is multicenter,
bottom-up designed, retrospective study aimed at evaluation of total cost of diabetes
type 2 in Poland. Study design reflects that of CODE-2 (Cost of Diabetes Type
2 in Europe) and allows for international comparison.
MATERIAL AND METHODS. Patients diagnosed with type 2 diabetes mellitus were randomly selected from outpatients charts databases and surveyed. Both patient and practitioner questionnaires collected data from each patient on: clinical characteristic, medical and other resources used, quality of life. Total treatment costs were calculated using drug retail and medical procedures prices. Indirect costs were estimated by human capital approach. The impact of complications on total costs was evaluated. Values are expressed in PLN and also presented in Euro value (PPP ‘2002 value: 1 EUR = 2.05 PLN).
RESULTS. 303 patients were enrolled (mean age: 61, mean time from diagnosis: 10.86 year, males: 49%). The total annual treatment costs amounted to 9227.20 PLN (4501.08 EUR), including 2429.95 PLN (1185.35 EUR) of direct costs. The direct cost structure: 11.1% physicians consultations, 2.9% paramedics, 17.3% oral antidiabetic drug, 29.1% insulins, 29.6% hospital costs, 0.8% emergency services, 9.2% laboratory tests. The indirect costs are mainly determined by early retirements or pension and relatives care costs.
CONCLUSIONS. Economic impact of diabetes type 2 in Poland is considerable. Drug prescription patterns, especially for insulin, are responsible for large part of direct costs.
MATERIAL AND METHODS. Patients diagnosed with type 2 diabetes mellitus were randomly selected from outpatients charts databases and surveyed. Both patient and practitioner questionnaires collected data from each patient on: clinical characteristic, medical and other resources used, quality of life. Total treatment costs were calculated using drug retail and medical procedures prices. Indirect costs were estimated by human capital approach. The impact of complications on total costs was evaluated. Values are expressed in PLN and also presented in Euro value (PPP ‘2002 value: 1 EUR = 2.05 PLN).
RESULTS. 303 patients were enrolled (mean age: 61, mean time from diagnosis: 10.86 year, males: 49%). The total annual treatment costs amounted to 9227.20 PLN (4501.08 EUR), including 2429.95 PLN (1185.35 EUR) of direct costs. The direct cost structure: 11.1% physicians consultations, 2.9% paramedics, 17.3% oral antidiabetic drug, 29.1% insulins, 29.6% hospital costs, 0.8% emergency services, 9.2% laboratory tests. The indirect costs are mainly determined by early retirements or pension and relatives care costs.
CONCLUSIONS. Economic impact of diabetes type 2 in Poland is considerable. Drug prescription patterns, especially for insulin, are responsible for large part of direct costs.
Keywords: Diabetes Mellitus Type 2costcost analysispharmacoeconomicsCODIPCODE-2